6533b851fe1ef96bd12a8da7
RESEARCH PRODUCT
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
Jean-david FumetEmeric LimagneEmeric LimagneMarion ThibaudinMarion ThibaudinFrançois Ghiringhellisubject
0301 basic medicineCancer Researchmedicine.medical_treatmentReviewchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemImmunityChemoimmunotherapyimmunogenic cell deathmedicinecancerChemotherapyimmunosuppressionbusiness.industryImmunosuppressionImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAcquired immune system030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchImmunogenic cell deathimmunotherapybusinessdescription
Simple Summary The aim of this review is to detailed immunological effects of chemotherapies focusing on 2 main effects: immunogenic cell death and depletion of suppressive cells. It provides a strong rational for combination of chemotherapy and immunotherapy. Abstract Chemotherapy is initially used to kill proliferative cells. In the current area of emerging immunotherapy, chemotherapies have shown their ability to modulate the tumor micro environment and immune response. We focus here on two main effects: first, immunogenic cell death, defined as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in immunocompetent hosts; and second, the depletion of suppressive cells, known to play a major role in immune escape and resistance to immunotherapy. In this review, we present a review of different classically used chemotherapies focusing on this double effect on immunity. These immunological effects of chemotherapy could be exploited to promote efficacy of immunotherapy. Broadening our understanding will make it possible to provide rationales for the combination of chemoimmunotherapy in early clinical trials.
year | journal | country | edition | language |
---|---|---|---|---|
2020-09-01 | Cancers |